News coverage about Mylan N.V. (NASDAQ:MYL) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mylan N.V. earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8964827485973 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Mylan N.V. (NASDAQ:MYL) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS (americanbankingnews.com)
- Mylan N.V. (MYL) Short Interest Up 10.1% in July (americanbankingnews.com)
- Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada – PR Newswire (press release) (prnewswire.com)
- Mylan N.V. (MYL) Stock Rating Reaffirmed by BMO Capital Markets (americanbankingnews.com)
- Mylan N.V. (NASDAQ:MYL) Receives “Buy” Rating from UBS AG (americanbankingnews.com)
MYL has been the subject of several recent analyst reports. Royal Bank Of Canada decreased their price objective on shares of Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating for the company in a research report on Thursday, May 11th. Wells Fargo & Company reiterated a “market perform” rating and set a $40.00 price objective on shares of Mylan N.V. in a research report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, May 25th. BidaskClub upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $47.00 to $50.00 in a research report on Monday, May 22nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $47.83.
Shares of Mylan N.V. (MYL) traded down 4.37% during mid-day trading on Friday, reaching $30.88. 11,080,764 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $37.34 and its 200-day moving average price is $39.01. The stock has a market cap of $16.52 billion, a price-to-earnings ratio of 24.96 and a beta of 1.27. Mylan N.V. has a 12-month low of $29.58 and a 12-month high of $49.42.
Mylan N.V. (NASDAQ:MYL) last posted its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by $0.08. The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. Mylan N.V.’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.16 EPS. Equities research analysts forecast that Mylan N.V. will post $4.68 earnings per share for the current year.
In other Mylan N.V. news, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now owns 140,653 shares in the company, valued at approximately $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Mylan N.V. (NASDAQ:MYL) Earning Somewhat Favorable News Coverage, Study Finds” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/08/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-mylan-n-v-nasdaqmyl-share-price-updated-updated-updated.html.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.